GNA Biosolutions named as winner of AACC Disruptive Technology Award

GNA Biosolutions was named the winner of the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award competition, held on Monday evening at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, Illinois. The AACC Disruptive Technology Award recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high-quality testing. GNA Biosolutions also won the audience choice award.

GNA presented data from the company’s proprietary Pulse Controlled Amplification (PCA) technology, which allows for ultrafast (15 minutes or less), sample-to-result workflows even on challenging clinical matrices such as whole blood. After launching a first PCA instrument (Pharos V8) at the end of 2017, GNA now plans to launch a portable and low-cost sample-to-result platform for infectious disease molecular testing at the Point of Care.

The planned assay pipeline for GNA’s CLIA-waivable POC platform focuses on antimicrobial-resistant pathogens that are highly relevant causes of hospital acquired infections, as well as multi-drug resistant tuberculosis (MDR-TB), an emerging challenge and risk for global health.

“We are honored to receive the Disruptive Technology Award from the AACC” said GNA Biosolutions co-founder and Managing Director Lars Ullerich. “Being recognized for our PCA technology is a proud moment for our whole team and we look forward to delivering it to the Point of Care.”

The company is also engaged in strategic partnerships to bring PCA-enabled ultrafast sample-to-answer workflows to applications across multiple industries. PCA is uniquely scalable from single-sample applications at the POC, to high-throughput applications in centralized laboratories.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    GNA Biosolutions GmbH. (2019, June 18). GNA Biosolutions named as winner of AACC Disruptive Technology Award. News-Medical. Retrieved on August 04, 2020 from https://www.news-medical.net/news/20180810/GNA-Biosolutions-named-as-winner-of-AACC-Disruptive-Technology-Award.aspx.

  • MLA

    GNA Biosolutions GmbH. "GNA Biosolutions named as winner of AACC Disruptive Technology Award". News-Medical. 04 August 2020. <https://www.news-medical.net/news/20180810/GNA-Biosolutions-named-as-winner-of-AACC-Disruptive-Technology-Award.aspx>.

  • Chicago

    GNA Biosolutions GmbH. "GNA Biosolutions named as winner of AACC Disruptive Technology Award". News-Medical. https://www.news-medical.net/news/20180810/GNA-Biosolutions-named-as-winner-of-AACC-Disruptive-Technology-Award.aspx. (accessed August 04, 2020).

  • Harvard

    GNA Biosolutions GmbH. 2019. GNA Biosolutions named as winner of AACC Disruptive Technology Award. News-Medical, viewed 04 August 2020, https://www.news-medical.net/news/20180810/GNA-Biosolutions-named-as-winner-of-AACC-Disruptive-Technology-Award.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.